ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on February 20, 2026, covering events occurring on February 20, 2026, and February 25, 2026. The filing primarily addresses executive leadership transitions within the finance department and references the upcoming release of financial results for the full year 2025 and the quarter ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in a press release (Exhibit 99.1) to be issued on February 25, 2026, but the numerical data is not included in this document.
Material Changes and Executive Transitions
- Departure of CFO: Brad Tade is retiring as Chief Financial Officer and Treasurer effective February 25, 2026. He will transition to a consulting role.
- Appointment of New CFO: Terry Kohler, previously the Executive Financial Advisor, has been promoted to Chief Financial Officer and Treasurer, effective February 26, 2026.
- Compensation for Outgoing CFO: Under a new Consulting Agreement, Mr. Tade will receive a monthly gross payment of $41,666.67 commencing in March 2026 through July 31, 2026. He retains eligibility for equity vesting during this term.
- Compensation for Incoming CFO: Mr. Kohler's employment agreement includes a base salary of $500,000 annually and a target cash bonus of 45% of base salary. He was granted 91,166 stock options and 58,019 restricted stock units (RSUs) with four-year vesting schedules.
Outlook, Risks, and Contingencies
The filing details significant severance and change-of-control provisions for the new CFO, Terry Kohler. In the event of termination without Cause, resignation for Good Reason, or a Change of Control, Mr. Kohler is entitled to severance ranging from six to nine months of base salary, prorated bonuses, COBRA premium reimbursement, and accelerated vesting of all equity awards. The filing notes that the financial results for 2025 will be announced via press release on February 25, 2026, but does not provide specific guidance or risk factors within this text.
Investor Verification Checklist
- Verify the specific financial results for the full year 2025 and Q4 2025 in the press release (Exhibit 99.1) referenced in Item 2.02.
- Review the full Separation and Consulting Agreements (Exhibit 10.1) to understand the total cost and duration of the transition for the outgoing CFO.
- Examine the Employment Agreement (Exhibit 10.2) for details on performance milestones tied to Mr. Kohler's bonus and the specific definitions of "Cause" and "Good Reason."
- Confirm the impact of the CFO transition on the company's upcoming 2025 Form 10-K filing timeline.